Grupo Televisa: Q2 Earnings Snapshot
The Mexico City-based company said it had net income of 5 cents per share.
The media company posted revenue of $755.7 million in the period.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TV at https://www.zacks.com/ap/TV
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Domino's opening fewer stores because of labour cost increases
Domino's Pizza Group has said it has opened fewer stores than expected as its franchisees have been 'cautious' due to higher labour costs linked to the Government's last budget. The pizza delivery specialist warned it would miss its original profit guidance for the year as it also highlighted 'weaker' sentiment among consumers, causing shares to plunge in early trading. It is among high street hospitality firms to have cautioned over 'tougher' market conditions recently, with Greggs also reporting pressure on customer demand last month. On Tuesday, the pizza chain – which has 1,381 stores in the UK and Ireland – said sales growth has been impacted by 'weak' consumer confidence in recent months. Andrew Rennie, chief executive of Domino's, said: 'There's no getting away from the fact that the market has become tougher both for us and our franchisees, and that's meant that the positive performance across the first four months didn't continue into May and June. 'Given weaker consumer confidence, increased employment costs and uncertainty ahead of the autumn statement, franchisees are taking a more cautious approach to store openings for the time being.' It said this has caused a 'short-term slowdown' in new stores but stressed that it expects this to pick up again next year. Domino's has opened 11 new stores so far this year and expects overall openings in the 'mid-20s' this financial year. The company had previously said it expected to open 'in excess of 50 new stores' this year. It came as the group also warned that profits would miss previous guidance due to weaker trading. Domino's told shareholders that it expects to deliver earnings between £130 million and £140 million for the year. It had previously said it was due to meet market expectations of between £140.8 million and £149.7 million. It came as the business revealed that system sales grew 1.3% to £777.8 million for the 26 weeks to June 29. Like-for-like sales were 0.1% lower for the half-year, as a positive first quarter was offset by a 0.7% decline in the second quarter, when delivery orders 'weakened'. The group added that 'softer' trading improved towards the end of July. Shares in Domino's Pizza Group fell by 19.4% to 198.2p in early trading on Tuesday. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Diageo shares pop on 'reassuring results' for fiscal 2025
-- Diageo (NYSE:DEO) (LON:DGE) reported annual organic sales growth that exceeded analyst expectations, sending its shares roughly 5% higher in London trading. For the fiscal year ended June (FY25), net sales came in at $20.25 billion, down 0.1% on a reported basis but up 1.7% organically. That compares with company-compiled consensus estimates of $20.2 billion and a 1.4% organic increase. Earnings per share (EPS) reached 164.2 cents, ahead of the 161.6 cents expected. Pretax profit fell to $3.54 billion from $5.46 billion a year earlier, while EBIT declined 0.7%, though still slightly better than the 1.2% drop analysts had forecast. "We would expect shares to be better today as the business doubles down on the controllables," Jefferies analyst Edward Mundy said in a note. "As recovery becomes visible, we would expect leverage through the i/s, improving free cash flow (FCF) and better returns, which will allow the shares to rerate to north of 20x PE," he added. Separately, BofA analysts said Diageo delivered "reassuring results in an uncertain environment." Looking ahead, Diageo expects organic net sales growth in fiscal 2026 to be in line with this year's pace, citing a continued challenging environment. Organic operating profit is projected to grow at a mid-single-digit rate, above the 2.6% consensus cited by Jefferies. Related articles Diageo shares pop on 'reassuring results' for fiscal 2025 Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett Apollo economist warns: AI bubble now bigger than 1990s tech mania Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships
The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong healthcare infrastructure in North America and Europe, and rising demand in Asia-Pacific, the market is poised for continued expansion, despite challenges like high R&D costs and complex regulations. Leading companies include Merck, Dynavax, and Moderna, with future growth focusing on personalized medicine, next-gen platforms, and oncology research funding. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035" report has been added to global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term immune memory and minimal side effects. Immunotherapy's success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities. The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines. Key Topics Covered: 1. Global Cancer Vaccine Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cancer Vaccine Market, by Vaccine Type, $Million, 2023-20352.1 Preventive Vaccines2.1.1 Gardasil2.1.2 HEPLISAV-B2.2 Therapeutic Vaccines2.2.1 Bacillus Calmette-Guerin (BCG)2.2.2 Sipuleucel-T (Provenge)3. Global Cancer Vaccine Market, by Technology Type, $Million, 2023-20353.1 Recombinant3.2 Cell-based3.3 Others4. Global Cancer Vaccine Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cancer Vaccine Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cancer Vaccine Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cancer Vaccine Market, by Country4.3.3.1 Japan5. Global Cancer Vaccine Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View Merck & Co., Inc., Dynavax Technologies Corporation Dendreon Pharmaceuticals LLC Moderna, Inc BioNTech SE Transgene S.A. Imugene Limited Ose-Immuno Barinthus Biotherapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
